SAQs Flashcards

SAQ

1
Q

Question

A

Answer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

a) Name three file types used in an NGS analysis pipeline (3)

A

3 from: FASTQBAM or SAM or CRAMVCFBED

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

b) For each of these file types describe their contents and use. (6) fastq, bam, vcf, bed

A

FASTQ- Text file containing sequence reads and associated quality informationStandard format containing all reads from sequencing. Can be analysed to generate quality metrics, and used as input for read alignment tools.BAM or SAM or CRAM- aligned/mapped reads and associated quality informationOutput of read alignment. Can be analysed to generate quality metrics.VCF - data lines containing information about a position in the genome, usually variants. May also include annotationsOutput of variant calling. Annotations may be added prior to variant filtering and analysis.BED - Genomic regions (chromosome, start and end)Used to define the regions of interest for the assay.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

c) NGS analysis often involves aligning short DNA sequences (reads) to a reference genome. Give two reasons why a read might not align correctly to the reference. (2)

A

Two from:Read maps to multiple locations in the reference genome (e.g. pseudogene)Reference genome is incomplete so sequence is missing (e.g. centromeric regions)Errors introduced during sequencingVariants in the sequence compared to reference

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

d) Reads that do not map uniquely to the reference genome (i.e. map to more than one location) are given a mapping score of 0 and may be excluded from downstream analysis. Explain possible reasons for non-unique mapping and what impact this might have on the clinical use of NGS. (3)

A

Duplicated regions of the genome (segmental duplications, pseudogenes) can result in the same sequence being present in 2 or more locations in the genome. NGS sequence reads that map to these duplicated regions will not have unique mapping and therefore may be removed from downstream analyses. If clinically relevant genes have a pseudogene it may be difficult to get sufficient coverage of the gene for variant calling. Alternatively, called variants may be in the pseudogene and not the gene itself. An alternate method may be required to confirm results in these genes such as long range PCR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

e) Give an example of a gene and an associated genetic disorder that might be difficult to analyse by NGS because reads do not map uniquely to the reference (2)

A

Possible examples: SMN1 and Spinal Muscular Atrophy or PMS2 and Lynch Syndrome(both have pseudogenes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Briefly describe paired-end sequencing and explain the advantages of paired-end over single-end sequencing for detecting variants associated with human disease. (4)

A

paired-end sequencing- Sequence both ends of the DNA fragment.Paired-end sequencing can be useful for detecting structural variants (deletions, insertions or inversions)- read pairs mapping to different locations in the genome give information about the position of that sequence. This is not possible with single-end sequencing. Structural variants are a common cause of genetic variation and therefore genetic disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the underlying genetic cause of fragile x?

A

FRAX is an X-linked recessive triplet repeat expansion disorder caused by a CGGrepeat expansion within the 5’ UTR of the FMR1 gene on the X-chromosome. Whenthe triplet repeat expands beyond a threshold (>200 repeats), this causeshypermethylation of the FMR1 promotor and silencing of the gene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe PCR for sizing?

A

The sizing PCR is a standard PCR with a F & R primer (one of which is fluorescentlylabelled). Products are separated by capillary electrophoresis and sized against amolecular ladder.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

describe TP-PCR

A

TP-PCR uses F & R primers (again one of which is fluorescently labelled) and also a thirdprimer which is specific to the triplet repeat. The third primer is added in a limitedmanner so that it is exhausted in early PCR rounds. This is to avoid preferentialamplification of smaller alleles. The products from the TP-PCR are also separated bycapillary electrophoresis and sized. A full expansion allele gives a classic ‘ski-slope’pattern which tails off towards the larger end of the repeat.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

a) List three differences between the nuclear and mitochondrial genomes

A

The mitochondrial genome is a fraction of the size of the nuclear genome (~16.5kb)The mitochondrial genome is a small circular moleculeMitochondrial DNA is maternally-inherited only.Mitochondrial has no introns and very few genes ~37

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the inheritance patterns associated with mitochondrial disease

A

Mitochondrial disease can be caused by pathogenic variants in the mtDNA itself (maternallyinherited only) or by pathogenic variants in nuclear genes involved in mitochondrial DNAmaintenance which can be autosomal dominant or recessive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Define the term heteroplasmy and homoplasmy and mitochondrial bottleneck

A

Heteroplasmy – where two or more different variants of mtDNA exist within a cellHomoplasmy – where all copies of the mtDNA are identical within a cell.Mitochondrial bottleneck – a random shift of mtDNA mutational load between generations(and even siblings) due to unequal transfer of mtDNA molecules during oogenesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe 3 considerations for interpretation of pathogenicity unique to mtDNA variants

A

There are currently no mitochondrial DNA specific guidelines for interpreting variants.Inheritance pattern (maternal or nuclear)Population databases used (Mitomap instead of gnomAD for example)check heter/homoplasmy levels in proband vs mum – if homoplasmic variant inherited from homoplasmic unaffected mum its unlikely to be disease- causing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clinicians have referred an adult presenting with optic neuropathy to the highly specialised mitochondrial diagnostic service. Describe the appropriate testing pathway and any relevant candidate genes and variants for targeted analysis

A

Optic neuropathy is a generic term and can be caused by pathogenic variants in mtDNA(such as Leber’s hereditary optic neuropathy (LHON)) or nuclear DNA. There are commonLHON variants which can be easily identified/excluded such as m.11778G>A (MT-ND4),m.3460G>A (MT-ND1) and m.14484T>C (MT-ND6).If these are negative, full gene screens can commence for each of the above threementioned genes.f full gene screens are negative, a nuclear based eye panel may be appropriate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Name the gene responsible for encoding mitochondrial DNA polymerase

A

POLG (polymerase gamma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is copy number variation?

A

A loss or gain of a region of the genome (could be single exon, multi-exon, wholegene or multiple genes).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What types of genetic/genome abnormalities can oligoarray NOT detect

A

Uniparental disomyBalanced translocationsTriploidy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe the differences between a SNP and oligo array?

A

An oligo array uses the patient and a sex-matched control sample which compete forhybridisation to the probes on the array slide. The patient and the control DNAs arelabelled in different fluorescence and the captured image is converted to show if thepatient has a gain or loss compared to the control sample.SNP arrays use thousands of known SNP positions across the genome and each SNPis genotyped into AA homozygotes, BB homozygotes and AB and BA heterozygotes.The patient is genotyped at each SNP position which is used to calculate the ratio ofAA, BB, AB and BA SNPs at each position and determine the copy number by theratio of heterozygous and homozygous SNPs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Briefly explain the use of the 3 resources/databases that you would use to aid interpretation of the clinical significance of a copy number change.

A

Database of Genomic Variation (DGV) – the DGV ‘gold standard’ track providesinformation on the frequency of your copy number variant in the population. Forexample, a CNV with a frequency of 0.80% in a population of 17,000 would be toohigh to be disease causing.ClinGen – This resource provides information on dosage pathogenicity and gives ahaploinsufficiency score and a triplosensitivity score for each gene in the CNV call.For example a haploinsufficiency score of 3 would automatically make the CNVpathogenic.Decipher – Large database with national patient cohort. This can be used todetermine if your CNV has been seen before, the phenotype of the patient/s withthis CNV, the reporting laboratory and any overlapping features with similarpatients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Briefly describe a known microdeletion syndrome region involving chromosome 16; include location, key gene(s) involved and provide two clinical features.

A

16p11.2 microdeletion syndrome which includes the TBX6 gene. Patients with thisdisorder have intellectual disability, developmental delay and some also have autisticbehaviours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Many newly described microdeletion or microduplication syndromes detected bymicroarray are subject to reduced penetrance and variable expressivity. Define theseterms.

A

Reduced penetrance – Not all people with the genetic change will display thefeatures associated with that disorder.Variable expressivity – The phenotype of the disorder is variable amongstindividuals, even those within the same family.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

a) Give 3 clinical features of Prader Willi syndrome.

A

Intellectual disabilityObesityHypotonia in infancyHyperphagiaOvergrowthstrabismus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Give 3 clinical features of Angelman syndrome.

A

SeizuresCharacteristic hand movementsInappropriate laughter

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

AS PWAS Define the chromosomal region associated with these conditions.

A

15q11.2-15q13

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

List the different mechanisms that may result in Angelman syndrome together withtheir recurrence risk for future pregnancies.

A

Paternal chromosome 15 UPD – <1-2%Maternal deletion of the 15q11.2-q13 region (likely de novo, low recurrence unlessgermline mosaicism)UBE3A pathogenic variant – 50%Imprinting control centre deletion (up to 50% recurrence)Imprinting control centre defect (<1%) (

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Describe two testing methods by which a Prader-Willi case may be geneticallyconfirmed.

A

Methylation-specific PCRMethylation-specific MLPA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Name 3 other imprinting disorders.

A

Beckwith-Wiedemann syndromeSilver-Russell syndromeTemple syndromeTransient neonatal diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

A 5 month old infant girl presents with a diagnosis of B-lineage Acute LymphoblasticLeukaemia (ALL)Describe the priority setting and testing strategy for this sample?

A

This would be classed as an urgent referralFISH for the common t(4;11) (MLL gene and AF4) translocation found in infant ALL – ifnegative proceed to ETV6/RUNX1 FISH which will also detect iAMP21 and BCR/ABL1FISH As BCR-ABL1, ETV6-RUNX1, iAMP21 and MLL rearrangements are thoughtto be mutually exclusive, if one abnormality is detected it is not mandatory toexclude others.If there is normal/failed result, ALL BPGs suggest additional FISH to detect hiddenhyper/hypodiploidy.Extract DNA for SNP arrayRNA extraction for fusion panel analysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

5 month old infant girl presents with a diagnosis of B-lineage Acute LymphoblasticLeukaemia (ALL)What would be the most common/likely chromosome abnormality detected in thispatient and give the prognosis. Include ISCN for abnormality and name the genesinvolved.

A

46,XX,t(4;11)(q21;q23) – poor prognosis, MLL gene and AF4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

c) The patient is negative for the above abnormality. The ETV6-RUNX1 dual fusion probe for this patient shows two fusion, one red, and one green signal pattern (2F1R1G). What does this pattern suggest the patient carries and what prognosis does it confer?

A

They are positive for the ETV6/RUNX1 fusion which confers a favourable prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

If the ETV6-RUNX1 dual fusion FISH probe showed a loss of the green ETV6 signal(2F1R0G), what would this indicate loss of and how would this effect the prognosis?

A

Loss of the normal chromosome 12 – prognosis does not change.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

e) Give two other chromosomal abnormalities seen in ALL that could be detected using the ETV6-RUNX1 probe other than the rearrangement in part C).

A

Loss of the red RUNX1 signal would indicate loss of the normal chromosome 21Amplification of the red signal would indicate iAMP 21 (intrachromosomal amplification of chromosome 21)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

describe the process of QF-PCR?

A

amplification of STRs on chromosomes of interest used to determine copy number‚óè STRs (short tandem repeats or microsatellites) are a pattern of 2 - 6 bp that are repeated directly adjacent to each other. ‚óè STRs are known highly polymorphic markers; a patient is therefore likely to have different numbers of repeat units on each allele.- 4 markers for each chromosome of interest and sex chromosome markers if referral indicates sex chromosome abnormality eg. AMEL, SRY and DXYS218(Xp) and X22- quantitative pcr - extracted DNA added to fluorescent primer multiplex and pcr. The reaction must be quantitative to detect copy number, therefore the PCR is stopped while in exponential phase to detect copy number -“ During the exponential phase of the reaction, the amount of product is directly proportional to amount of template “- rapid, cheap, small quantities of DNA needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

following a positive qf-PCR result, what other tests would you offer?

A
  • sample identity must be confirmed prior to reporting (N.B. by a repeat test of the original sample or genotype comparison with a maternal blood sample- karyotype to visualize abnormal rearrangements- normal results based on a single marker should be confirmed by a second method, e.g. karyotype or FISH.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

what are Characteristics of cffDNA?

A

-placenta - shed highly fragmented DNA into the maternal circulation during normal apoptosisthe total cell free DNA in maternal plasma that comes from the placenta (up to 20%)- reliably detected from 7 weeks- increases with increasing gestation- rapidly cleared from circulation within an hour after delivery - fetal DNA is shorter -approximately 200bp for fetal fragments and larger for maternal fragments.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

how do you calculate fetal fraction?

A

dividing the amount of reads mapped to chromosome Y by the total amount of reads mapped to autosomal chromosomes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

define heteroplasmy

A

which two or more mtDNA variants exist within the same cell

39
Q

what is mitochondrial donation ?

A

ooctye donation or nuclear transfer where the nuclear genome from the oocyte or embryo of an affected woman is transplanted into a donor enucleated oocyte or embryo with healthy mt. nuclear DNA can be transferred between unfertilised oocytes using polar body transfer or maternal spindle transfer or between fertilised zygotes using pronuclear transfer

40
Q

what genes/mutations are involved in Leigh syndrome?

A

MT-ATP6 m.8993T>C (also MT-ND1, 4 and 6)Encephalopathy, lactic acidosis

41
Q

MDS - what are common chromosomal abnormalities as well as prognosis?

A

-5q deletion (15% of cases) - good prognosis if isolated finding. low risk of transforming to AML. TP53 mutation testing recommended in WHO as presence of mutation and del(5q) predicts poor response to lenolidomide-monosomy 7 - poor prognosis (more common in therapy-related MDS)- trisomy 8- intermediate- complex (3 or more abnormalities often TP53 locus) 90% of therapy related-MDS - poor prognosis

42
Q

what do the new WHO 2016 leukaemia guidelines contain updates for?

A

new clinical, prognostic, morphologic, immunophenotypic, and genetic data that have emerged since the last editionmorphology = blood and marrow smears morphologically examined using Giemsa stain. blast count >20%immunophenotyping = examine expression of cell-surface markers using flow-cytometry cytogenetics - chromosomal abnormalities in 55% of adult AML casesmolecular genetics- screening for mutations ina) NPM1, CEBPA, and RUNX1 genes b) FLT3 - ITD, WT/M ratio and D835 and I836 tyrosine kinase domain mutations3)TP53 and ASXL1 - poor prognosis RT-PCR for recurrent gene-fusions. initiated when cytogenetics fails. following identification of a translocation by karyotype and for cryptic gene fusions where cytogenetic abnormality not present. also used to monitor MRD.

43
Q

give two abnormalities in AML (include breakpoints) associated with good prognosis?

A

t(8;21)(q22;q22) - RUNX1T1-RUNX1inv(16)(p13q22)t(15;17)(q24.1;q21.2) - PML- RARA

44
Q

give two abnormalities in AML (include breakpoints) associated with poor prognosis?

A

t(9;22)(q34;q11) 5q abnormalities

45
Q

CML – what is the common resistant mutation and treatment?

A

NAME?

46
Q

what is the most common ALL abnormality in 1-25 years?

A

t(12;21) ETV6-RUNX1 t(12;21)(p13;q22)good prognosis

47
Q

what is the most common (50%) ALL abnormality in infants <1 year?

A

MLL translocation t(4;11)(q21;q23) poor prognosis

48
Q

after MLL rearrangements and ETV6-RUNX1, what is the 3rd-line test for B-ALL in < 1 years?

A

1) t(9;22)(q34;q11) BCR-ABL1 rearrangement (4%)poor prognosis

49
Q

what is the most common rearrangement in T-ALL?

A

TCR (T-cell receptor) rearrangements - usually placed next to transcription factorsunknown prognosis

50
Q

what is the most significant genetic prognostic factors for adult ALL?

A

t(9;22)(q34;q11) BCR-ABL1 Philadelphia chromosome - 30% of adult ALL casespoor prognosis

51
Q

what is the second-line test in adult B-ALL? what is the prognosis?

A

t(4;11)(q21;q23) MLL (chr11) AF4(chr4)poor prognosis

52
Q

other than (4;11)(q21;q23) MLL ; AF4 what other common rearrangements involving MLL are found in ALL?

A

o t(9;11)o t(11;19)

53
Q

other than BCR:ABL1, MLL rearrangements and ETV6-RUNX1 what other common rearrangements are found in ALL?

A
  • high hyperdiploidy (51-56 chromosomes) - good prognosis- hypodiploidy <44 chromosomes- TCF3 rearrangements- IGH rearrangements- Dic (9;12)- Dic(9;20)Abn/del(9p)
54
Q

what files do you need to have ready for a new start up?

A

induction plan - Who will they need to meet, what training will they needPersonal Development Plan - forms part of probationSecurity - Request for ID/Access Card form request a basic IT account Mandatory trainingContractNew Starter form - PAY

55
Q

SMA result homozygous of the common mutation, and one parent is a carrier and the other is negative, how do you explain that?

A

4% of population have two copies of SMN1 on one chromosome non paternitysample mixupde novoallele dropout - polymorphism

56
Q

PWS/SMA hypotonia question, name other types of dystrophies?

A

myotonic dystrophy

57
Q

PWS/SMA name other types of dystrophies and genes involved?

A

myotonic dystrophy - DMPK & ZNF9 (DM2)FSHD - AD contraction of D4Z4 repeats (contains DUX4 gene)CMD - TTN LMNA MYH7DMD/BMD - DMD

58
Q

Expansion repeats (CAG repeats polyQ, give three examples, other than spinocerebral ataxias).

A
  1. HD - HTT gene2. SBMA - XLR - AR gene (also causes androgen insensitivity syndrome) 3. dentatorubral-pallidoluysian atrophy (DRPLA) - CAG expansion in ATN1 geneAll exonic! GOF - CAG repeat expansions result in polyglutamine aggregates
59
Q

What are the repeat sizes with normal, intermediate and full mutation for HD and Frax.

A

FRAX N up to 4546-58 intpremutation 59-200mutation >200HD6-26 N27-35 int36-39 red pen>39 complete penetrance

60
Q

what is anticipation?

A

trinucleotide repeat expansions in successive generations in which the signs and symptoms of some genetic conditions tend to become more severe, more frequent or occur at an earlier age

61
Q

what is the most common EGFR mutation in NSCLC lung cancer? what is the most common resistant mutation?

A

18bp in-frame deletion in exon 19 (c.2240_2257del) and a common point mutation in exon 21 (p.L858R) (90%). GOF activating mutations.p.T790M mutation is the most common resistant mutation and is found in ~50% of patients that develop acquired resistance to tyrosine kinase inhibitors

62
Q

Define SNV and give other examples of mutations

A

A DNA sequence variation that occurs when a single nucleotide (adenine, thymine, cytosine, or guanine) in the genome sequence is alteredsubstitutiondeletioninsertionduplicationinversiondelins

63
Q

what is evidence for variant pathogenicity?

A

null variantSame amino acid change as a previously established (likely) pathogenic variant de novofunctional studiesprevalence of the variant in affected individuals is significantly increased compared with the prevalence in controlsmutation hotspotabsent from controlsFor recessive disorders, detected in trans with a (likely) pathogenic variantProtein length changes as a result of in-frame deletions/insertions in a non-repeat region missense change at an amino acid residue where a different missense change determined to be likely pathogenic has been seen beforesegregationMissense variant in a gene that has a low rate of benign missense variation Multiple lines of computational evidence support a deleterious effect - (conservation, evolutionary, splicing impacthighly specific phenotypereputable source

64
Q

define validation?

A

validation = ‘Confirmation, through the provision of objective evidence, that the requirements for a specific intended use or application have been fulfilled’ (doing correct test)Validation is required when there is no suitable performance specification available and the performance characteristics of the test need to be defined.with the almost complete absence of reference tests or certified reference materials, the reference should be the most reliable diagnostic method available

65
Q

define verification?

A

verification = ‘Confirmation, through the provision of objective evidence, that specified requirements have been fulfilled’ (doing test correctly)’ If a suitable performance specification is available, it is necessary to check that the new test meets this specification within the laboratory (verification). Verification is also appropriate when a new test is introduced that uses a well-established method within the lab.

66
Q

what is positive predictive value?

A

he likelihood that an individual with a positive test result truly has the particular gene and/or disease in questiontrue positives/true positives + false positives

67
Q

what is negative predictive value?

A

he likelihood that an individual with a negative test result is truly unaffected and/or does not have the particular gene mutation in questiontrue negatives/true negs + false negs

68
Q

why might there be elevated neonatal IRT apart from CF?

A

neonatal stress (low Apgars), respiratory distress, hypoglycaemia, or serious congenital abnormalities such as trisomies 13 and 18PPV is low for IRT

69
Q

what is the CF testing pathway for a newborn with high IRT on first 5 day test?

A

screen 4 most common variants accounting for 80% of variants seen in the UK population. If a single variant detected or two variants (immediate referral to a CF specialist), screen for all variants. 2nd IRT on day 28 if first is raised. If no mutation identified but still high > CF suspected. If one mutation detected but still high > CF suspected. If one mutation detected and IRT normal on 2nd test = probable carrier.

70
Q

combined test which two markers included in that test?

A

free beta human chorionic gonadotropin (bhCG) and pregnancy associated plasma protein-A (PAPP-A)

71
Q

what DS screening markers first and second trimester?

A

1st trimesterNT - detects 60% of casesserum markers PAPP-A and free betaabsent nasal bonedoppler evaluation for regurgitated blood flowlimb abnormalities - short long bones2nd trimester18 week scan:cardiac defectsduodenal atresia- closure in the first part of their small intestinesoft:echogenic bowelsandal gap

72
Q

DMD – treatments available?

A
  • stop codon readthrough eg. translana. 15% of patients have PTC. Tretments allows alternative amino acids to be inserted at the site of the mutated stop codon & results in dystophin expression at 10-20% providing some function- exon skipping eg. exondys51 (80% of patients in theory). Interferes with splicing skipping the specific exon in DMD pre-mRNA to restore open reading frame and allow expression of shorter but functional protein
73
Q

how are CML patients tested in the lab?

A

-G-banding analysis on blood or marrow of 10 cells and BCR/ABL1 FISH test for cryptic or variant translocations-It is useful to carry out molecular analysis to confirm the presence of BCR::ABL1 gene rearrangement (TR-PCR) and to determine the nature of the rearrangement for future Minimal Residual Disease (MRD) analysis.-Patients with a positive result will benefit from treatment with Imatinib- also scan for secondary abnormalities including +Ph, +8, +19, +21, -Y, i(17q).

74
Q

describe the gene structure during transcription/translation

A

Transcription (DNA > mRNA)Gene = Promoter (proximal and core) > 5’UTR> start codon (open reading frame) to stop codon> 3’UTRPromoter is 5’ and consists of core and proximal (most 5’). Core promoter contains RNA polymerase binding site, TATA box (transcription factors bind) and proximal contains TF binding sites. 5’ UTR spans TSS to start codon. Binds ribosome. 3’ UTR immediately follows stop codon. contains terminator sequence (endpoint for transcription where RNA polymerase released), regulatory regions and polyadenylation signal which directs addition and cleavage of polyA tail to end of mRNA transcript (important for stabulity and nuclear export)RNA is complimentary to DNA. undergoes splicing to remove introns and exons are joined. 5’ capping and 3’poly-A tail addedTranslation (mRNA > protein)mRNA consists of 5’ cap, 5’UTR, coding segment, 3’UTR and polyA signal

75
Q

Mention an example where the testing of a gene would be important for a particular drug dosage

A

DPYD metabolizes 5FU chemo drug-DPYD variants may cause poor metabolism and so dose-management is critical to prevent toxicity. -heterozygotes usually asymptomatic but homozygotes may have epilepsy and motor dysfunction. - 4 known variants affect protein function and lead to increased toxicity- the 4 variants are given different activity values- depending on whether hom, het or compound het the DPD activity is classified into normal, intermediate or poor metabolisers- intermediate metabolisers should reduce dose by 50%. dose is then adjusted depending on toxicity- NHS england provide this service to all patients prior to 5FU chemo- warfarin prevents clotting in thromboembolism- metabolised by CYP2C9- polymorphisms in CYP2C9 contribute to variability in dose requirement (15% variation in warfarin response)- overdosing leads to excessive bleeding- limited genotyping in the UK

76
Q

what would you include in a VUS report?

A
  • Only report if hot/warm VUS which high level of supporting evidence and where additional evidence might upgrade eg. parents, further testing (imaging/biochem/muscle), mRNA in recommended action and how it might change classification- treatment trials if available- ‚ÄòNo clearly pathogenic sequence variants were detected.- Diagnosis not confirmed- clinical significance of the unclassified variant is uncertain6 and presymptomatic testing in unaffected family members is not recommended.
77
Q

AML translocation (8;21) - what would you write in the report, mention 2x other leukaemia translocations that involve 21.

A

Good prognosis proportion of neoplastic cells in the sampletesting methodresultinterpretationclinical trialsnotes and referencesALL: t(12;21)(p13;q22) ETV6-RUNX1 good prognosisALL: iAMP(21) - poor prognosisMDS/AML t(3;21)(q26. 2;q22) - Therapy-Related Disease Associated With Poor Outcome

78
Q

what tests/techniques can you do with AML

A

karyotype + FISHFISH for del(5q), del(7q) and monosomy 7 and 17p (TP53) will detect myelodysplastic related changesRT-PCR to characterise breakpoints and monitoringNGS panel testing for the identification of driver variants within RUNX1, TP53, FLT3 is mandatory (may be germline origin) - skin biopsy.

79
Q

molar pregnancy - mechanisms, tests, features, how would you treat the mother

A

complete mole = Only paternal chromosomes; diploid. empty egg and two sperm or duplicated sperm. symptoms = hypertension, oedema (fluid) and vaginal bleeding, increased uterus size, risk of trophoblastic diseasepartial hydatidiform mole : Double paternal contribution i.e. two paternal sets and one maternal set of chromosomes eg. 69, XXY, 69,XXX or 69,XYY - fertilisation of a normal egg by 2 sperm (dispermy), duplicated or diploid spermIUGR, neural tube defects, Oligohydramnios (too little fluid), Large placenta (cystic), later on - syndactyly (webbed fingers or toes) and hydrocephaly (fluid on brain)• Blood tests will show very high levels of hCG- ultrasound scan - the mole resembles a bunch of grapes- • A definitive diagnosis requires histopathological examinationtreatments: Suction evacuation , monitor hCG levels, • Chemotherapy recommended if Metastases identified or rising levels of hCG

80
Q

array CNV investigation - how would you evaluate the gene content. databases you would look at. what is a high haploinsufficiency score ?

A

CNV genomic content: size,overlap with established triplosensitive (TS), haploinsufficient (HI) or benign genes/genomic regions; gene number and content population frequency, evaluation of literature, public databases, internal lab data; inheritance pattern/family history for patient being studied- multiple unrelated patients with a similar CNV and a consistent phenotype (more likely pathogenic)- de novo supports pathogenicity. Additional weight is given if the phenotype is highly specific and relatively unique to the gene/genomic region.- Segregation amongst similarly affected family members supports pathogenicity• Non-segregations EXCEPT incomplete penetrance, phenocopies (variation caused by environment that resembles a genetic variation), accurate phenotyping of family members, age of onset and inheritance pattern - for a CNV identified in recessive gene - look for SNV on other alleleloss of one allele resulting in a single normal allele at a particular locus is inadequate for normal function resulting in a phenotype. Regions of copy number loss containing established HI genes are more likely to be pathogenic. HI info available on ClinGen, decipher, knockout mouse models, literature, ClinVar, HGMD, OMIMpLI available on GnoMad

81
Q

Beckwith Wiedemann - clinical features (mention 4), genes involved, other tests you could do

A

NAME?

82
Q

FFPE sample - issues and how would you overcome. examples of tests you can do from FFPE samples?

A
  • variable quality depending on size of resection, amount of time in formalin or whether recalcified (bone samples - unsuitable for testing)- extracted DNA is fragmented- more PCR artefacts due to deamination of cytosine>uracil - results in C>T/G>A transition sequencing artefacts - low tumour %- need specific technologies to detect low-level mutation- Tumour heterogeneity - mutation may only be present in part of tumour- test failure due to poor quality/quantity- is labour intensive - hard to have fast TATs (eg. EGFR testing in Lung cancer up to 2 weeks)- lynch, breast solid, NSCLC
83
Q

|Cancer: genes associated with treatment in Lung, CRC, mention 2x genes you would test in Melanoma

A

inherited cutaneous malignant melanoma - CDKN2A or CDK4EGFR mutation - Gefitinib if mutatedEGFR + KRAS - if WT cetuximabBRAF - MEK inhibitorOsimertinib 2nd line treatment can be given to EGFR+ and T790M EGFR inhibitor resistance lung cancers

84
Q

what is sensitivity?

A

Sensitivity is the ability of a test to correctly identify individuals who are affected by a disease, (the true positive rate)True positives/true positives + false negatives

85
Q

what is specificity?

A

the ability of a test to correctly identify individuals who are not affected by a disease, (the true negative rate)true negatives/true negatives + false positives

86
Q

FRAX - boy with 72 repeats. risks, implications to family. other than direct PCR what tests can you do in FRAX (mention 4).

A

FXTAS (50%) - over 60 years onset- expansion to full mutation exclusive to females and usually if >90 repeats - risk to other family memberssouthern blot - detects all sizes and methylation but laborious, large amounts of DNA required, doesnt have the resolution to detect sizeAmplidex - detects normal, premutation and full mutations +some detect methylation, AGG repeats but expensive as a first-line testlinkage - STR markers. may be useful in prenatal eg. if southern blot fails. NGS - SNVs, deletions, duplications

87
Q

Williams, whole X mosaic del, PLS (Potocki-Lupski syndrome – chr 17p 11.2 dup) , DiGeorge, - mention relevant genes

A

williams 7q11.2 - ELN (Elastin)PLS (Potocki-Lupski syndrome – chr 17p 11.2 dup retinoic acid inducible 1 (RAI1) geneX chromosome - SHOX (Xp22) AR (Xq12) XIST (Xq13)Di George 22q11.2 TBX1

88
Q

Xp deletion in a male - mention gene, other tests you could do, clinical symptoms?

A

SHOX - Xp22.33short stature Leri-Weill dyschondrosteosis (LWD) - short stature, scoliosis, FISH, array, karyotype

89
Q

AZF deletion found and there were 2 X. and write the possible karyotype. possible explanation. mention gene examples involved in DSD.

A

47,XX,del(Y)(q11), 47,XX,+idic(Y)(q11.21) or 47,XX,+idic(Yp)? 47,XX,+r(Y) - breakpoint Yq11.2formation of isochromosomefusion of p arm to q arm

90
Q

mention 4 genes involved in DSD?

A

MaleSRY - 46,XX male Disorder of Sex Development (DSD).SOX9 - gonadal dysgenesisSF1- gonadal dysgenesisWT1- gonadal dysgenesisFemale WNT4RSPO1FOXL2AR - androgen insensitivityCYP21A2 - CAH

91
Q

X-linked condition about ornithine syndrome. Define and give example of X-linked recessive, X-linked dominant, Autosomal dominant with reduced penetrance.

A

Xp11.4 OTC genelack of the OTC enzyme results in excessive accumulation of ammoniaSymptoms include vomiting, refusal to eat, progressive lethargy, and comaX linked recessive = mutation in a gene on the X chromosome causes the phenotype to be always expressed in males and in females who are homozygous eg. DMD, OTC deficiency (more severe in males), SBMAX linked dominant = In females a mutation in a gene on one of the X chromosomes is enough to cause the condition. Fragile X, rett syndromeAD reduced penetrance = BRCA, HD

92
Q

cf in newborn screen- high IRT, 2 mutations, what further tests would you do and importance

A

test parents to confirm zygosity and provide risk (1/4) to future pregnanciesoffer testing to other family members if appropriate

93
Q

BRCA question - synonymous variant at the end of the exon no effect on protein change and not reported anywhere. how would you classify, what would you do.

A

vussplicing predictions? recommend functional studies, RNA analysis, minigene assay

94
Q

what docs do you need ready for new starter?

A

induction plan - Who will they need to meet, what training will they needPersonal Development Plan - forms part of probationSecurity - Request for ID/Access Card form request for basic IT account Mandatory trainingContractNew Starter form – PAY